**[EPI\_720 - T01] New Users of abiraterone + prednisone with CRPC**

*Initial Event Cohort*

People having any of the following:

* a drug exposure of [RWE CTF] Abiraterone (Zytiga)4
  + for the first time in the person's history

with continuous observation of at least 365 days prior and 0 days after event index date, and limit initial events to: **earliest event per person.**

For people matching the Primary Events, include:

Having all of the following criteria:

* at least 1 occurrences of a drug exposure of [EPI\_693] Oral predniso(lo)ne3

where event starts between 30 days Before and 30 days After index start date

* and at least 1 occurrences of a condition occurrence of Primary malignant neoplasm of prostate2

where event starts between all days Before and 0 days Before index start date

* And having any of the following criteria:
  + at least 1 occurrences of a drug exposure of CPRC Definition Androgen Deprivation Therapy1

where event starts between all days Before and 30 days Before index start date

* + or at least 1 occurrences of a procedure of CPRC Definition Androgen Deprivation Therapy1

where event starts between all days Before and 30 days Before index start date

Limit cohort of initial events to: **earliest event per person.**

Limit qualifying cohort to: **earliest event per person.**

*End Date Strategy*

Custom Drug Era Exit Criteria

This strategy creates a drug era from the codes found in the specified concept set. If the index event is found within an era, the cohort end date will use the era's end date. Otherwise, it will use the observation period end date that contains the index event.

Use the era end date of [RWE CTF] Abiraterone (Zytiga)4

* allowing 30 days between exposures
* adding 0 days after exposure end

*Cohort Collapse Strategy:*

Collapse cohort by era with a gap size of 0 days.

**[EPI\_720 - T01] New Users of abiraterone + prednisone with CRPC (no CVD in prior 6-mo)**

*Initial Event Cohort*

People having any of the following:

* a drug exposure of [RWE CTF] Abiraterone (Zytiga)6
  + for the first time in the person's history

with continuous observation of at least 365 days prior and 0 days after event index date, and limit initial events to: **earliest event per person.**

For people matching the Primary Events, include:

Having all of the following criteria:

* at least 1 occurrences of a drug exposure of [EPI\_693] Oral predniso(lo)ne3

where event starts between 30 days Before and 30 days After index start date

* and at least 1 occurrences of a condition occurrence of Primary malignant neoplasm of prostate2

where event starts between all days Before and 0 days Before index start date

* And having any of the following criteria:
  + at least 1 occurrences of a drug exposure of CPRC Definition Androgen Deprivation Therapy1

where event starts between all days Before and 30 days Before index start date

* + or at least 1 occurrences of a procedure of CPRC Definition Androgen Deprivation Therapy1

where event starts between all days Before and 30 days Before index start date

Limit cohort of initial events to: **earliest event per person.**

*Inclusion Rules*

Inclusion Criteria #1: CVD in 6 months prior to index date

Having all of the following criteria:

* exactly 0 occurrences of a condition occurrence of [EPI\_720] Conditions indicating established CVD (strata)4

where event starts between 180 days Before and 0 days Before index start date

* and exactly 0 occurrences of a procedure of [EPI\_720] Procedures indicating established CVD (strata)5

where event starts between 180 days Before and 0 days Before index start date

Limit qualifying cohort to: **earliest event per person.**

*End Date Strategy*

Custom Drug Era Exit Criteria

This strategy creates a drug era from the codes found in the specified concept set. If the index event is found within an era, the cohort end date will use the era's end date. Otherwise, it will use the observation period end date that contains the index event.

Use the era end date of [RWE CTF] Abiraterone (Zytiga)6

* allowing 30 days between exposures
* adding 0 days after exposure end

*Cohort Collapse Strategy:*

Collapse cohort by era with a gap size of 0 days.

**[EPI\_720 - T01] New Users of abiraterone + prednisone with CRPC (any CVD in prior 6-mo)**

*Initial Event Cohort*

People having any of the following:

* a drug exposure of [RWE CTF] Abiraterone (Zytiga)6
  + for the first time in the person's history

with continuous observation of at least 365 days prior and 0 days after event index date, and limit initial events to: **earliest event per person.**

For people matching the Primary Events, include:

Having all of the following criteria:

* at least 1 occurrences of a drug exposure of [EPI\_693] Oral predniso(lo)ne3

where event starts between 30 days Before and 30 days After index start date

* and at least 1 occurrences of a condition occurrence of Primary malignant neoplasm of prostate2

where event starts between all days Before and 0 days Before index start date

* And having any of the following criteria:
  + at least 1 occurrences of a drug exposure of CPRC Definition Androgen Deprivation Therapy1

where event starts between all days Before and 30 days Before index start date

* + or at least 1 occurrences of a procedure of CPRC Definition Androgen Deprivation Therapy1

where event starts between all days Before and 30 days Before index start date

Limit cohort of initial events to: **earliest event per person.**

*Inclusion Rules*

Inclusion Criteria #1: CVD in 6 months prior to index date

Having any of the following criteria:

* at least 1 occurrences of a condition occurrence of [EPI\_720] Conditions indicating established CVD (strata)4

where event starts between 180 days Before and 0 days Before index start date

* or at least 1 occurrences of a procedure of [EPI\_720] Procedures indicating established CVD (strata)5

where event starts between 180 days Before and 0 days Before index start date

Limit qualifying cohort to: **earliest event per person.**

*End Date Strategy*

Custom Drug Era Exit Criteria

This strategy creates a drug era from the codes found in the specified concept set. If the index event is found within an era, the cohort end date will use the era's end date. Otherwise, it will use the observation period end date that contains the index event.

Use the era end date of [RWE CTF] Abiraterone (Zytiga)6

* allowing 30 days between exposures
* adding 0 days after exposure end

*Cohort Collapse Strategy:*

Collapse cohort by era with a gap size of 0 days.

**[EPI\_720 - T01] New Users of abiraterone + prednisone with CRPC (less severe CVD in prior 6-mo)**

*Initial Event Cohort*

People having any of the following:

* a drug exposure of [RWE CTF] Abiraterone (Zytiga)6
  + for the first time in the person's history

with continuous observation of at least 365 days prior and 0 days after event index date, and limit initial events to: **earliest event per person.**

For people matching the Primary Events, include:

Having all of the following criteria:

* at least 1 occurrences of a drug exposure of [EPI\_693] Oral predniso(lo)ne3

where event starts between 30 days Before and 30 days After index start date

* and at least 1 occurrences of a condition occurrence of Primary malignant neoplasm of prostate2

where event starts between all days Before and 0 days Before index start date

* And having any of the following criteria:
  + at least 1 occurrences of a drug exposure of CPRC Definition Androgen Deprivation Therapy1

where event starts between all days Before and 30 days Before index start date

* + or at least 1 occurrences of a procedure of CPRC Definition Androgen Deprivation Therapy1

where event starts between all days Before and 30 days Before index start date

Limit cohort of initial events to: **earliest event per person.**

*Inclusion Rules*

Inclusion Criteria #1: less evere CVD: <=2 conditions AND <=2 procedures

Having all of the following criteria:

* at most 2 distinct occurrences of a condition occurrence of [EPI\_720] Conditions indicating established CVD (strata)4

where event starts between 180 days Before and 0 days Before index start date

* and at most 2 distinct occurrences of a procedure of [EPI\_720] Procedures indicating established CVD (strata)5

where event starts between 180 days Before and 0 days Before index start date

Inclusion Criteria #2: less severe CVD: >1 condition OR >1 procedures

Having any of the following criteria:

* at least 1 distinct occurrences of a condition occurrence of [EPI\_720] Conditions indicating established CVD (strata)4

where event starts between 180 days Before and 0 days Before index start date

* or at least 1 distinct occurrences of a procedure of [EPI\_720] Procedures indicating established CVD (strata)5

where event starts between 180 days Before and 0 days Before index start date

Limit qualifying cohort to: **earliest event per person.**

*End Date Strategy*

Custom Drug Era Exit Criteria

This strategy creates a drug era from the codes found in the specified concept set. If the index event is found within an era, the cohort end date will use the era's end date. Otherwise, it will use the observation period end date that contains the index event.

Use the era end date of [RWE CTF] Abiraterone (Zytiga)6

* allowing 30 days between exposures
* adding 0 days after exposure end

*Cohort Collapse Strategy:*

Collapse cohort by era with a gap size of 0 days.

**[EPI\_720 - T01] New Users of abiraterone + prednisone with CRPC (less severe CVD in prior 6-mo)**

*Initial Event Cohort*

People having any of the following:

* a drug exposure of [RWE CTF] Abiraterone (Zytiga)6
  + for the first time in the person's history

with continuous observation of at least 365 days prior and 0 days after event index date, and limit initial events to: **earliest event per person.**

For people matching the Primary Events, include:

Having all of the following criteria:

* at least 1 occurrences of a drug exposure of [EPI\_693] Oral predniso(lo)ne3

where event starts between 30 days Before and 30 days After index start date

* and at least 1 occurrences of a condition occurrence of Primary malignant neoplasm of prostate2

where event starts between all days Before and 0 days Before index start date

* And having any of the following criteria:
  + at least 1 occurrences of a drug exposure of CPRC Definition Androgen Deprivation Therapy1

where event starts between all days Before and 30 days Before index start date

* + or at least 1 occurrences of a procedure of CPRC Definition Androgen Deprivation Therapy1

where event starts between all days Before and 30 days Before index start date

Limit cohort of initial events to: **earliest event per person.**

*Inclusion Rules*

Inclusion Criteria #1: less severe CVD: <=2 conditions AND <=2 procedures

Having all of the following criteria:

* at most 2 distinct occurrences of a condition occurrence of [EPI\_720] Conditions indicating established CVD (strata)4

where event starts between 180 days Before and 0 days Before index start date

* and at most 2 distinct occurrences of a procedure of [EPI\_720] Procedures indicating established CVD (strata)5

where event starts between 180 days Before and 0 days Before index start date

Inclusion Criteria #2: less severe CVD: >1 condition OR >1 procedures

Having any of the following criteria:

* at least 1 distinct occurrences of a condition occurrence of [EPI\_720] Conditions indicating established CVD (strata)4

where event starts between 180 days Before and 0 days Before index start date

* or at least 1 distinct occurrences of a procedure of [EPI\_720] Procedures indicating established CVD (strata)5

where event starts between 180 days Before and 0 days Before index start date

Limit qualifying cohort to: **earliest event per person.**

*End Date Strategy*

Custom Drug Era Exit Criteria

This strategy creates a drug era from the codes found in the specified concept set. If the index event is found within an era, the cohort end date will use the era's end date. Otherwise, it will use the observation period end date that contains the index event.

Use the era end date of [RWE CTF] Abiraterone (Zytiga)6

* allowing 30 days between exposures
* adding 0 days after exposure end

*Cohort Collapse Strategy:*

Collapse cohort by era with a gap size of 0 days.

**[EPI\_720 - T01] New Users of abiraterone + prednisone with CRPC (more severe CVD in prior 6-mo)**

*Initial Event Cohort*

People having any of the following:

* a drug exposure of [RWE CTF] Abiraterone (Zytiga)6
  + for the first time in the person's history

with continuous observation of at least 365 days prior and 0 days after event index date, and limit initial events to: **earliest event per person.**

For people matching the Primary Events, include:

Having all of the following criteria:

* at least 1 occurrences of a drug exposure of [EPI\_693] Oral predniso(lo)ne3

where event starts between 30 days Before and 30 days After index start date

* and at least 1 occurrences of a condition occurrence of Primary malignant neoplasm of prostate2

where event starts between all days Before and 0 days Before index start date

* And having any of the following criteria:
  + at least 1 occurrences of a drug exposure of CPRC Definition Androgen Deprivation Therapy1

where event starts between all days Before and 30 days Before index start date

* + or at least 1 occurrences of a procedure of CPRC Definition Androgen Deprivation Therapy1

where event starts between all days Before and 30 days Before index start date

Limit cohort of initial events to: **earliest event per person.**

*Inclusion Rules*

Inclusion Criteria #1: More Severe CVD: >2 conditions OR > 2 procedures

Having any of the following criteria:

* at least 3 distinct occurrences of a condition occurrence of [EPI\_720] Conditions indicating established CVD (strata)4

where event starts between 180 days Before and 0 days Before index start date

* or at least 3 distinct occurrences of a procedure of [EPI\_720] Procedures indicating established CVD (strata)5

where event starts between 180 days Before and 0 days Before index start date

Limit qualifying cohort to: **earliest event per person.**

*End Date Strategy*

Custom Drug Era Exit Criteria

This strategy creates a drug era from the codes found in the specified concept set. If the index event is found within an era, the cohort end date will use the era's end date. Otherwise, it will use the observation period end date that contains the index event.

Use the era end date of [RWE CTF] Abiraterone (Zytiga)6

* allowing 30 days between exposures
* adding 0 days after exposure end

*Cohort Collapse Strategy:*

Collapse cohort by era with a gap size of 0 days.

**[EPI\_720 - C01] New users of enzalutamide with CRPC**

*Initial Event Cohort*

People having any of the following:

* a drug era of Enzalutamide2
  + for the first time in the person's history

with continuous observation of at least 365 days prior and 0 days after event index date, and limit initial events to: **earliest event per person.**

For people matching the Primary Events, include:

Having all of the following criteria:

* at least 1 occurrences of a condition occurrence of Primary malignant neoplasm of prostate3

where event starts between all days Before and 0 days Before index start date

* And having any of the following criteria:
  + at least 1 occurrences of a drug exposure of CPRC Definition Androgen Deprivation Therapy1

where event starts between all days Before and 0 days Before index start date

* + or at least 1 occurrences of a procedure of CPRC Definition Androgen Deprivation Therapy1

where event starts between all days Before and 0 days Before index start date

Limit cohort of initial events to: **earliest event per person.**

Limit qualifying cohort to: **earliest event per person.**

*End Date Strategy*

Custom Drug Era Exit Criteria

This strategy creates a drug era from the codes found in the specified concept set. If the index event is found within an era, the cohort end date will use the era's end date. Otherwise, it will use the observation period end date that contains the index event.

Use the era end date of Enzalutamide2

* allowing 30 days between exposures
* adding 0 days after exposure end

*Cohort Collapse Strategy:*

Collapse cohort by era with a gap size of 0 days.

**[EPI\_720 - C01] New users of enzalutamide with CRPC (no CVD in prior 6-mo)**

*Initial Event Cohort*

People having any of the following:

* a drug era of Enzalutamide2
  + for the first time in the person's history

with continuous observation of at least 365 days prior and 0 days after event index date, and limit initial events to: **earliest event per person.**

For people matching the Primary Events, include:

Having all of the following criteria:

* at least 1 occurrences of a condition occurrence of Primary malignant neoplasm of prostate3

where event starts between all days Before and 0 days Before index start date

* And having any of the following criteria:
  + at least 1 occurrences of a drug exposure of CPRC Definition Androgen Deprivation Therapy1

where event starts between all days Before and 0 days Before index start date

* + or at least 1 occurrences of a procedure of CPRC Definition Androgen Deprivation Therapy1

where event starts between all days Before and 0 days Before index start date

Limit cohort of initial events to: **earliest event per person.**

*Inclusion Rules*

Inclusion Criteria #1: CVD in 6 months prior to index date

Having all of the following criteria:

* exactly 0 occurrences of a condition occurrence of [EPI\_720] Conditions indicating established CVD (strata)4

where event starts between all days Before and all days After index start date

* and exactly 0 occurrences of a procedure of [EPI\_720] Procedures indicating established CVD (strata)5

where event starts between all days Before and all days After index start date

Limit qualifying cohort to: **earliest event per person.**

*End Date Strategy*

Custom Drug Era Exit Criteria

This strategy creates a drug era from the codes found in the specified concept set. If the index event is found within an era, the cohort end date will use the era's end date. Otherwise, it will use the observation period end date that contains the index event.

Use the era end date of Enzalutamide2

* allowing 30 days between exposures
* adding 0 days after exposure end

*Cohort Collapse Strategy:*

Collapse cohort by era with a gap size of 0 days.

**[EPI\_720 - C01] New users of enzalutamide with CRPC (any CVD in prior 6-mo)**

*Initial Event Cohort*

People having any of the following:

* a drug era of Enzalutamide2
  + for the first time in the person's history

with continuous observation of at least 365 days prior and 0 days after event index date, and limit initial events to: **earliest event per person.**

For people matching the Primary Events, include:

Having all of the following criteria:

* at least 1 occurrences of a condition occurrence of Primary malignant neoplasm of prostate3

where event starts between all days Before and 0 days Before index start date

* And having any of the following criteria:
  + at least 1 occurrences of a drug exposure of CPRC Definition Androgen Deprivation Therapy1

where event starts between all days Before and 0 days Before index start date

* + or at least 1 occurrences of a procedure of CPRC Definition Androgen Deprivation Therapy1

where event starts between all days Before and 0 days Before index start date

Limit cohort of initial events to: **earliest event per person.**

*Inclusion Rules*

Inclusion Criteria #1: CVD in 6 months prior to index date

Having any of the following criteria:

* at least 1 occurrences of a condition occurrence of [EPI\_720] Conditions indicating established CVD (strata)4

where event starts between all days Before and all days After index start date

* or at least 1 occurrences of a procedure of [EPI\_720] Procedures indicating established CVD (strata)5

where event starts between all days Before and all days After index start date

Limit qualifying cohort to: **earliest event per person.**

*End Date Strategy:*

Custom Drug Era Exit Criteria

This strategy creates a drug era from the codes found in the specified concept set. If the index event is found within an era, the cohort end date will use the era's end date. Otherwise, it will use the observation period end date that contains the index event.

Use the era end date of Enzalutamide2

* allowing 30 days between exposures
* adding 0 days after exposure end

*Cohort Collapse Strategy:*

Collapse cohort by era with a gap size of 0 days.

**[EPI\_720 - C01] New users of enzalutamide with CRPC (less severe CVD in prior 6-mo)**

*Initial Event Cohort*

People having any of the following:

* a drug era of Enzalutamide2
  + for the first time in the person's history

with continuous observation of at least 365 days prior and 0 days after event index date, and limit initial events to: **earliest event per person.**

For people matching the Primary Events, include:

Having all of the following criteria:

* at least 1 occurrences of a condition occurrence of Primary malignant neoplasm of prostate3

where event starts between all days Before and 0 days Before index start date

* And having any of the following criteria:
  + at least 1 occurrences of a drug exposure of CPRC Definition Androgen Deprivation Therapy1

where event starts between all days Before and 0 days Before index start date

* + or at least 1 occurrences of a procedure of CPRC Definition Androgen Deprivation Therapy1

where event starts between all days Before and 0 days Before index start date

Limit cohort of initial events to: **earliest event per person.**

*Inclusion Rules*

Inclusion Criteria #1: less severe CVD: <=2 conditions AND <=2 procedures

Having all of the following criteria:

* at most 2 distinct occurrences of a condition occurrence of [EPI\_720] Conditions indicating established CVD (strata)4

where event starts between 180 days Before and 0 days Before index start date

* and at most 2 distinct occurrences of a procedure of [EPI\_720] Procedures indicating established CVD (strata)5

where event starts between 180 days Before and 0 days Before index start date

Inclusion Criteria #2: less severe CVD: >1 condition OR >1 procedures

Having any of the following criteria:

* at least 1 distinct occurrences of a condition occurrence of [EPI\_720] Conditions indicating established CVD (strata)4

where event starts between 180 days Before and 0 days Before index start date

* or at least 1 distinct occurrences of a procedure of [EPI\_720] Procedures indicating established CVD (strata)5

where event starts between 180 days Before and 0 days Before index start date

Limit qualifying cohort to: **earliest event per person.**

*End Date Strategy*

Custom Drug Era Exit Criteria

This strategy creates a drug era from the codes found in the specified concept set. If the index event is found within an era, the cohort end date will use the era's end date. Otherwise, it will use the observation period end date that contains the index event.

Use the era end date of Enzalutamide2

* allowing 30 days between exposures
* adding 0 days after exposure end

*Cohort Collapse Strategy:*

Collapse cohort by era with a gap size of 0 days.

**[EPI\_720 - C01] New users of enzalutamide with CRPC (more severe CVD in prior 6-mo)**

*Initial Event Cohort*

People having any of the following:

* a drug era of Enzalutamide2
  + for the first time in the person's history

with continuous observation of at least 365 days prior and 0 days after event index date, and limit initial events to: **earliest event per person.**

For people matching the Primary Events, include:

Having all of the following criteria:

* at least 1 occurrences of a condition occurrence of Primary malignant neoplasm of prostate3

where event starts between all days Before and 0 days Before index start date

* And having any of the following criteria:
  + at least 1 occurrences of a drug exposure of CPRC Definition Androgen Deprivation Therapy1

where event starts between all days Before and 0 days Before index start date

* + or at least 1 occurrences of a procedure of CPRC Definition Androgen Deprivation Therapy1

where event starts between all days Before and 0 days Before index start date

Limit cohort of initial events to: **earliest event per person.**

*Inclusion Rules*

Inclusion Criteria #1: more severe CVD: >2 conditions OR >2 procedures

Having any of the following criteria:

* at least 3 distinct occurrences of a condition occurrence of [EPI\_720] Conditions indicating established CVD (strata)4

where event starts between 180 days Before and 0 days Before index start date

* or at least 3 distinct occurrences of a procedure of [EPI\_720] Procedures indicating established CVD (strata)5

where event starts between 180 days Before and 0 days Before index start date

Limit qualifying cohort to: **earliest event per person.**

*End Date Strategy*

Custom Drug Era Exit Criteria

This strategy creates a drug era from the codes found in the specified concept set. If the index event is found within an era, the cohort end date will use the era's end date. Otherwise, it will use the observation period end date that contains the index event.

Use the era end date of Enzalutamide2

* allowing 30 days between exposures
* adding 0 days after exposure end

*Cohort Collapse Strategy:*

Collapse cohort by era with a gap size of 0 days.

**[EPI\_720 - O01] Cardiovascular morbidity (hospitalization for ischemic stroke, hemorrhagic stroke, heart failure, acute myocardial infarction or sudden cardiac death)**

*Initial Event Cohort*

People having any of the following:

* a condition occurrence of [LEGEND HTN] Ischemic stroke4
  + visit occurrence is any of: Inpatient Visit, Emergency Room Visit, Emergency Room and Inpatient Visit
* a condition occurrence of [LEGEND HTN] intracranial bleed Hemorrhagic stroke3
  + visit occurrence is any of: Inpatient Visit, Emergency Room Visit, Emergency Room and Inpatient Visit
* a condition occurrence of [LEGEND HTN] Heart Failure 2
  + visit occurrence is any of: Inpatient Visit, Emergency Room Visit, Emergency Room and Inpatient Visit
* a condition occurrence of [LEGEND HTN] Acute myocardial Infarction1
  + visit occurrence is any of: Inpatient Visit, Emergency Room Visit, Emergency Room and Inpatient Visit
* a condition occurrence of [LEGEND HTN] Sudden cardiac death5
  + visit occurrence is any of: Inpatient Visit, Emergency Room Visit, Emergency Room and Inpatient Visit
* an observation of [LEGEND HTN] Sudden cardiac death5
  + visit occurrence is any of: Inpatient Visit, Emergency Room Visit, Emergency Room and Inpatient Visit

with continuous observation of at least 0 days prior and 0 days after event index date, and limit initial events to: **all events per person.**

Limit qualifying cohort to: **all events per person.**

*End Date Strategy*

Date Offset Exit Criteria

This cohort definition end date will be the index event's start date plus 7 days

*Cohort Collapse Strategy:*

Collapse cohort by era with a gap size of 180 days.

**[EPI\_720 - O02] Cardiovascular morbidity - ischemic stroke hospitalization**

*Initial Event Cohort*

People having any of the following:

* a condition occurrence of [LEGEND HTN] Ischemic stroke1
  + visit occurrence is any of: Inpatient Visit, Emergency Room Visit, Emergency Room and Inpatient Visit

with continuous observation of at least 0 days prior and 0 days after event index date, and limit initial events to: **all events per person.**

Limit qualifying cohort to: **all events per person.**

*End Date Strategy*

Date Offset Exit Criteria

This cohort definition end date will be the index event's start date plus 7 days

*Cohort Collapse Strategy:*

Collapse cohort by era with a gap size of 180 days.

**[EPI\_720 - O03] Cardiovascular morbidity - hemorrhagic stroke hospitalization**

*Initial Event Cohort*

People having any of the following:

* a condition occurrence of [LEGEND HTN] intracranial bleed Hemorrhagic stroke1
  + visit occurrence is any of: Inpatient Visit, Emergency Room Visit, Emergency Room and Inpatient Visit

with continuous observation of at least 0 days prior and 0 days after event index date, and limit initial events to: **all events per person.**

Limit qualifying cohort to: **all events per person.**

*End Date Strategy*

Date Offset Exit Criteria

This cohort definition end date will be the index event's start date plus 7 days

*Cohort Collapse Strategy:*

Collapse cohort by era with a gap size of 180 days.

**[EPI\_720 - O04] Cardiovascular morbidity - heart failure hospitalization**

*Initial Event Cohort*

People having any of the following:

* a condition occurrence of [LEGEND HTN] Heart Failure 1
  + visit occurrence is any of: Inpatient Visit, Emergency Room Visit, Emergency Room and Inpatient Visit

with continuous observation of at least 0 days prior and 0 days after event index date, and limit initial events to: **all events per person.**

Limit qualifying cohort to: **all events per person.**

*End Date Strategy*

Date Offset Exit Criteria

This cohort definition end date will be the index event's start date plus 7 days

*Cohort Collapse Strategy:*

Collapse cohort by era with a gap size of 180 days.

**[EPI\_720 - O05] Cardiovascular morbidity - acute myocardial infarction (AMI) hospitalization**

*Initial Event Cohort*

People having any of the following:

* a condition occurrence of [LEGEND HTN] Acute myocardial Infarction1
  + visit occurrence is any of: Inpatient Visit, Emergency Room Visit, Emergency Room and Inpatient Visit

with continuous observation of at least 0 days prior and 0 days after event index date, and limit initial events to: **all events per person.**

Limit qualifying cohort to: **all events per person.**

*End Date Strategy*

Date Offset Exit Criteria

This cohort definition end date will be the index event's start date plus 7 days

*Cohort Collapse Strategy:*

Collapse cohort by era with a gap size of 180 days.

**[EPI\_720 - O06] Cardiovascular morbidity - sudden cardiac death (inpatient)**

*Initial Event Cohort*

People having any of the following:

* a condition occurrence of [LEGEND HTN] Sudden cardiac death1
  + visit occurrence is any of: Inpatient Visit, Emergency Room Visit, Emergency Room and Inpatient Visit
* an observation of [LEGEND HTN] Sudden cardiac death1
  + visit occurrence is any of: Inpatient Visit, Emergency Room Visit, Emergency Room and Inpatient Visit

with continuous observation of at least 0 days prior and 0 days after event index date, and limit initial events to: **all events per person.**

Limit qualifying cohort to: **all events per person.**

*End Date Strategy*

Date Offset Exit Criteria

This cohort definition end date will be the index event's start date plus 7 days

*Cohort Collapse Strategy:*

Collapse cohort by era with a gap size of 180 days.